Effects of severe hypertension on endothelial and platelet microparticles

Hypertension

Volumn 41, Issue 2, 2003, Pages 211-217

  Preston, Richard A ^a,b   Jy, Wenche ^a   Jimenez, Joaquin J ^a   Mauro, Lucia M ^a   Horstman, Lawrence L ^a   Valle, Madelyn ^a   Aime, Gerard ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Division of Clinical Pharmacology   (United States)

Author keywords

Cell adhesion molecules; Endothelium; Endothelium derived factors; Hypertension, arterial; Platelets

Indexed keywords

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTHELIUM; FEMALE; HUMAN; HYPERTENSION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE;

ADULT; BLOOD PLATELETS; BLOOD PRESSURE; CELL MEMBRANE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET ACTIVATION; SEVERITY OF ILLNESS INDEX;

EID: 0037315391     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000049760.15764.2D     Document Type: Article

References (50)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2444.
2. 1999 World Health Organization. International Society of Hypertension, Guidelines for the Management of Hypertension: guidelines subcommittee. J Hypertens. 1999;17:151-183.
3. Kaplan N. Hypertensive crises. In: Kaplan N. Clinical Hypertension. 7th ed. Baltimore, Md: Williams and Wilkins; 1998:265-280.
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129 mm Hg. JAMA. 1967;202:116-122.
5. Preston RA, Baltodano NM, Cienki J, Materson BJ. Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. J Hum Hypertens. 1999;13:249-255.
6. Preston RA, Materson BJ, Yoham MA, Anapol H. Hypertension in Haitians: pilot survey of a public teaching hospital multispecialty clinic. J Hum Hypertens. 1996;10:743-745.
7. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
8. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation. 2000;101:218-220.
9. Lip GYH, Blann AD, Beevers DG. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J Hypertens. 1999;17:1203-1207.
10. Ferri C, Bellini C, Desideri G, Giuliani E, De Siati L, Cicogna S, Santucci A. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension. 1998;32:862-868.
11. Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A, De Mattia G. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension. 1999;34:568-573.
12. Lip GYH, Edmunds E, Hee FLLS, Blann AD, Beevers DG. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens. 2001;14:823-828.
13. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences J Hypertens. 2000;18:363-374.
14. Park JB, Charbonneauc F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens. 2001;19:415-420.
15. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Piccoli A, Valentini U, Cimino A, Girelli A, Salvetti M, De Ciuceis C, Tiberio GAM, Giulini SM, Sleiman I, Monteduro C, Rosei AE. Endothelial dysfunction in small resistance arteries of patients with non-insulin-dependent diabetes mellitus. J Hypertens. 2001;19:913-919.
16. Vanhoutte PM. How to assess endothelial function in human blood vessels. J Hypertens. 1999;17:1047-1058.
17. Camilletti A, Moretti N, Giacchetti G, Faloia E, Martarelli D, Mantero F, Mazzanti L. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am J Hypertens. 2001;14:382-386.
18. Blann AD, Lip GY, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens. 1997;11:607-609.
19. Riondino S, Pignatelli P, Pulcinelli FM, Lenti L, Di Veroli C, Marigliano V, Gazzaniga PP. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc. 1999;47:943-947.
20. Verhaar MC, Beutler JJ, Gaillard CA, Koomans HA, Fijnheer R, Rabelink TJ. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens. 1998;16:45-50.
21. Tomoda F, Takata M, Kagitani S, Kinuno H, Yasumoto K, Tomita S, Inoue H. Different platelet aggregability during mental stress in two stages of essential hypertension. Am J Hypertens. 1999;12:1063-1070.
22. Dockrell ME, Walker BR, Noon JP, Watt GC, Williams BC, Webb DJ. Platelet aggregation in young men with contrasting predisposition to high blood pressure. Am J Hypertens. 1999;12:115-119.
23. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69-75.
24. Cadwgan TM, Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J Hypertens. 1993;11:417-420.
25. Combes V, Simon A-C, Grau G-E, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93-102.
26. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol. 2001;112:81-90.
27. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101:841-843.
28. Larkin M. Raised endothelial microparticles an early marker for multiple sclerosis? Lancet. 2001;357:1679.
29. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, Horstman LL, Ahn YS. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001;56:1319-1324.
30. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104:2649-2652.
31. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol/Hematol. 1999;30:111-142.
32. Tocchetti EV, Flower RL, Lloyd JV. Assessment of in vitro-generated platelet microparticles using a modified flow cytometric strategy. Thromb Res. 2001;103:47-55.
33. Nomura S, Nakamura T, Cone J, Tandon NN, Kambayashi J. Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. Cytometry. 2000;40:173-181.
34. Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, Ahn YS. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res. 1993;72:295-304.
35. Geiser T, Sturzenegger M, Genewein U, Haeberli A, Beer JH. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke. 1998;29:1770-1777.
36. Katopodis JN, Kolodny L, Jy W, Horstman LL, De Marchena EJ, Tao JG, Haynes DH, Ahn YS. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol. 1997;54:95-101.
37. Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res. 1995;79:163-174.
38. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119:334-345.
39. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood. 2000;95:1317-1323.
40. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost. 1999;82:794-800.
41. Merten M, Pakala R, Thiagarajan P, Benedict CR. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation. 1999;99:2577-2582.
42. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136-144.
43. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99:2118-2127.
44. Jy W, Mao WW, Horstman L, Tao J, Ahn YS. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis. 1995;21:217-231.
45. Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS. A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost. 1999;82:1255-1259.
46. Preston RA, Ledford M, Materson BJ, Baltodano NM, Memon M, Alonso A. Effects of severe, uncontrolled hypertension on endothelial activation: sVCAM-1, sICAM-1, and vWF. J Hypertens. 2002;20:871-877.
47. Jy W, Horstman LL, Park H, Mao WW, Valant P, Ahn YS. Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. Am J Hematol. 1998;57:33-42.
48. Jimenez JJ, Jy W, Mauro LM, Valle M, Horstman LH, Ahn YS. Endothelial cells (EC) release phenotypically distinct endothelial microparticles (EMP) in activation vs. apoptosis: findings in TTP patients. Blood. 2001;98:249A. Abstract number 1045.
49. Jy W, Horstman LL, Wang F, Duncan R, Ahn YS. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb Res. 1995;80:471-482.
50. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JN, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348-353.